April 12 Quick Takes: DiaSorin buying Luminex for $1.8B; plus Antios, Reneo, VectivBio, Pulmatrix, Taysha
DiaSorin S.p.A. (MTAA:DIA) is acquiring multiplexing technology company Luminex Corp. (NASDAQ:LMNX) for $1.8 billion in a deal that expands the Italian in vitro diagnostic company’s footprint in the U.S. and its molecular diagnostics portfolio. The combined entity would have had €1.3 billion ($1.5 billion) in revenues last year.
Soleus leads $96M series B for HBV play Antios
Antios Therapeutics Inc. raised $96 million in a series B round led by Soleus Capital with participation by new investors RA Capital, Adage Capital Management, Pontifax, Aisling Capital, Altium Capital, Amzak Health, Granite Point Capital Management and LifeSci Venture Partners, plus the company’s series A investors. Antios’ ATI-2173 is in Phase II testing to treat chronic HBV...